Establishment Labs (NASDAQ:ESTA) Shares Down 5.3%

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) traded down 5.3% during trading on Friday . The company traded as low as $49.28 and last traded at $49.80. 126,477 shares were traded during trading, a decline of 70% from the average session volume of 428,203 shares. The stock had previously closed at $52.57.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Citigroup boosted their price target on shares of Establishment Labs from $49.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Mizuho boosted their target price on shares of Establishment Labs from $50.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, April 1st. JPMorgan Chase & Co. boosted their target price on shares of Establishment Labs from $46.00 to $53.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Finally, Stephens reiterated an “overweight” rating and issued a $47.00 target price on shares of Establishment Labs in a report on Thursday, January 11th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $55.00.

Establishment Labs Price Performance

The business’s fifty day moving average is $46.65 and its 200 day moving average is $36.20. The firm has a market capitalization of $1.34 billion, a P/E ratio of -16.29 and a beta of 1.24. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 10.26.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Wednesday, February 28th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.16. The business had revenue of $31.60 million for the quarter, compared to the consensus estimate of $31.44 million. Establishment Labs had a negative net margin of 47.53% and a negative return on equity of 357.81%. The firm’s quarterly revenue was down 27.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.55) earnings per share. As a group, analysts forecast that Establishment Labs Holdings Inc. will post -1.58 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. increased its position in shares of Establishment Labs by 17.2% in the third quarter. Adage Capital Partners GP L.L.C. now owns 80,000 shares of the company’s stock worth $3,926,000 after acquiring an additional 11,736 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Establishment Labs by 357.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 30,247 shares of the company’s stock valued at $783,000 after purchasing an additional 23,639 shares in the last quarter. Legato Capital Management LLC grew its position in Establishment Labs by 63.1% during the fourth quarter. Legato Capital Management LLC now owns 8,438 shares of the company’s stock valued at $218,000 after purchasing an additional 3,263 shares in the last quarter. Bamco Inc. NY grew its position in Establishment Labs by 29.0% during the third quarter. Bamco Inc. NY now owns 333,777 shares of the company’s stock valued at $16,378,000 after purchasing an additional 75,000 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its position in Establishment Labs by 41.2% during the third quarter. Rice Hall James & Associates LLC now owns 368,407 shares of the company’s stock valued at $18,078,000 after purchasing an additional 107,441 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.